Spots Global Cancer Trial Database for stage iv renal cell cancer ajcc v7
Every month we try and update this database with for stage iv renal cell cancer ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients | NCT02599779 | Stage IV Renal ... | Pembrolizumab Stereotactic Bo... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03015740 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | NCT01239342 | Metastatic Kidn... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Akt Inhibitor M... Everolimus Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | NCT01664182 | Advanced Renal ... Advanced Sarcom... Stage III Renal... Stage IV Renal ... | Bevacizumab Pazopanib Hydro... Sorafenib Tosyl... Sunitinib Malat... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | NCT01038778 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Aldesleukin Computed Tomogr... Entinostat Fludeoxyglucose... Laboratory Biom... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | NCT01835158 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Cabozantinib S-... Laboratory Biom... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | NCT03050060 | Metastatic Kidn... Recurrent Lung ... Stage IV Cutane... Stage IV Renal ... Stage IV Lung N... | Atezolizumab Hypofractionate... Laboratory Biom... Nelfinavir Mesy... Nivolumab Pembrolizumab | 18 Years - | University of Washington | |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | NCT02595918 | Clear Cell Rena... Metastatic Rena... Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... | Metastasectomy Nephrectomy Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | NCT01239342 | Metastatic Kidn... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Akt Inhibitor M... Everolimus Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | NCT01198158 | Clear Cell Rena... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Bevacizumab Everolimus Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | NCT02626130 | Clear Cell Rena... Metastatic Rena... Stage IV Renal ... | Cryosurgery Laboratory Biom... Therapeutic Con... Tremelimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | NCT02761057 | Locally Advance... Metastatic Papi... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar... Unresectable Re... | Biospecimen Col... Bone Scan Cabozantinib S-... Computed Tomogr... Crizotinib Savolitinib Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | NCT02626130 | Clear Cell Rena... Metastatic Rena... Stage IV Renal ... | Cryosurgery Laboratory Biom... Therapeutic Con... Tremelimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | NCT00121251 | Recurrent Renal... Stage III Renal... Stage IV Renal ... | Capecitabine Gemcitabine Hyd... Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | NCT03334409 | Clear Cell Rena... Metastatic Clea... Stage III Renal... Stage IV Renal ... Unresectable Re... | Ascorbic Acid Pazopanib Hydro... | 18 Years - | Academic and Community Cancer Research United | |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | NCT01835158 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Cabozantinib S-... Laboratory Biom... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03015740 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | NCT01198158 | Clear Cell Rena... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Bevacizumab Everolimus Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | NCT01480154 | Advanced Malign... Stage III Cutan... Stage III Prost... Stage III Renal... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Stage IV Prosta... Stage IV Renal ... | Akt Inhibitor M... Hydroxychloroqu... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
